BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16803958)

  • 1. The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain.
    Plevin MJ; Zhang J; Guo C; Roeder RG; Ikura M
    Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10242-10247. PubMed ID: 16803958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
    Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
    Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
    Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
    Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.
    Corpora T; Roudaia L; Oo ZM; Chen W; Manuylova E; Cai X; Chen MJ; Cierpicki T; Speck NA; Bushweller JH
    J Mol Biol; 2010 Sep; 402(3):560-77. PubMed ID: 20708017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.
    Ahn EY; Yan M; Malakhova OA; Lo MC; Boyapati A; Ommen HB; Hines R; Hokland P; Zhang DE
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17103-8. PubMed ID: 18952841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E protein silencing by the leukemogenic AML1-ETO fusion protein.
    Zhang J; Kalkum M; Yamamura S; Chait BT; Roeder RG
    Science; 2004 Aug; 305(5688):1286-9. PubMed ID: 15333839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
    Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
    J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.
    Liu Y; Cheney MD; Gaudet JJ; Chruszcz M; Lukasik SM; Sugiyama D; Lary J; Cole J; Dauter Z; Minor W; Speck NA; Bushweller JH
    Cancer Cell; 2006 Apr; 9(4):249-60. PubMed ID: 16616331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO.
    Roh SH; Kasembeli M; Galaz-Montoya JG; Trnka M; Lau WC; Burlingame A; Chiu W; Tweardy DJ
    J Biol Chem; 2016 Feb; 291(9):4732-41. PubMed ID: 26706127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
    Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
    Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of multimer-mediated mayhem.
    Sitwala KV; Hess JL
    Cancer Cell; 2006 Apr; 9(4):241-2. PubMed ID: 16616328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
    Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
    Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AML1/ETO trans-activates c-KIT expression through the long range interaction between promoter and intronic enhancer.
    Tian Y; Wang G; Hu Q; Xiao X; Chen S
    J Cell Biochem; 2018 Apr; 119(4):3706-3715. PubMed ID: 29236325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
    Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
    Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.
    Gardini A; Cesaroni M; Luzi L; Okumura AJ; Biggs JR; Minardi SP; Venturini E; Zhang DE; Pelicci PG; Alcalay M
    PLoS Genet; 2008 Nov; 4(11):e1000275. PubMed ID: 19043539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
    Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
    Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.
    Maiques-Diaz A; Chou FS; Wunderlich M; Gómez-López G; Jacinto FV; Rodriguez-Perales S; Larrayoz MJ; Calasanz MJ; Mulloy JC; Cigudosa JC; Alvarez S
    Leukemia; 2012 Jun; 26(6):1329-37. PubMed ID: 22289984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery.
    Guo C; Hu Q; Yan C; Zhang J
    Mol Cell Biol; 2009 May; 29(10):2644-57. PubMed ID: 19289505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
    Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
    Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.